AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below Cash
- Written by Newsfile
New York, New York--(Newsfile Corp. - May 20, 2021) - PCG Digital -- Anthony Hayes is an optimist, with good reason. The CEO of AIkido Pharmaceuticals (NASDAQ: AIKI), according to the company's Q1 report and a press release recently issued, is expecting positive results from human clinical trials of dual-action peptide receptor radionuclide...